Top

International Journal of Public Health

Published in:

Open Access 01-04-2011 | Original Article

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

Authors: Nadia Demarteau, Bruno Detournay, Bertrand Tehard, Abdelkader El Hasnaoui, Baudouin Standaert

Published in: International Journal of Public Health | Issue 2/2011

Abstract

Objective

This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model.

Methods

A lifetime Markov cohort model, adapted to the French setting, simulate the natural history of oncogenic HPV infection towards cervical cancer (CC). Additional modules account for the effects of screening and vaccination. The girls’ cohort is vaccinated at age 12 and follows current screening. Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.

Results

The model results agreed well with real-life data. Vaccination in addition to screening would substantially reduce the incidence of and mortality from CC, compared with screening alone, at an estimated cost-effectiveness of €9,706 per quality-adjusted-life-year. Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.

Conclusion

This succinct cohort model indicated that HPV vaccination would be a cost-effective policy option in France. It uses readily available data and should be generally applicable to the evaluation of HPV vaccination in a variety of countries and settings.

Arveux P, Benard S, Bouee S, Lafuma A, Martin L, Cravello L, Remy V, Breugelmans JG (2007) Invasive cervical cancer treatment costs in France. Bull Cancer 94(2):219–224PubMed

Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, Bouguermouh S, Vienne Md ML, Agius G (2004) Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 73(2):262–268PubMedCrossRef

Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V (2006) Coût du depistage et de la prise en charge des lesions precancereuses du col uterin en France. Gynecologie Obstetrique Fertilite 34(11):1036–1042CrossRef

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24(1):10–19PubMedCrossRef

Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265PubMed

Boulanger JC, Sevestre H, Bauville E, Ghighi C, Harlicot JP, Gondry J (2004) Epidemiology of HPV infection. Gynecol Obstet Fertil 32(3):218–223PubMedCrossRef

Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84(12):1616–1623PubMedCrossRef

Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1):63–73PubMedCrossRef

Cochand-Priollet B, Vincent S, Vielh P (2004) Cytopathology in France. Cytopathology 15(3):163–166PubMedCrossRef

Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128–v149PubMedCrossRef

Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, Mougin C (2004) Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 40(8):1225–1232PubMedCrossRef

Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L (2008) Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26(Suppl 5):F16–F28PubMedCrossRef

Exbrayat C (2002) Col de l’utérus. In: Remontet L, Buemi A, Velten M, Jougla E, Esteve J (eds) Evolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000. Institut de Veille Sanitaire. Departement Maladies Chroniques et Traumatismes, Saint-Maurice Cédex, pp 107–112

Fahey MT, Irwig L, Macaskill P (1995) Meta-analysis of Pap test accuracy. Am J Epidemiol 141(7):680–689PubMed

Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Press. Available via IARC. Accessed August 2008

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008: Cancer incidence and mortality worldwide. International agency for research on cancer. Available via http://globocan.iarc.fr. Accessed June 2010

Gold MR, Franks P, McCoy KI, Fryback DG (1998) Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36(6):778–792PubMedCrossRef

Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA (1999) The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 130(2):97–107PubMed

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604–615PubMedCrossRef

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa-Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367(9518):1247–1255PubMedCrossRef

Insinga R, Glass A, Rush B. (2005) Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses. (Abstract W-02 presented at 22nd International Papillomavirus Conference and Clinical Workshop 2005, Vancouver, Canada, April 30–May 6)

Institut National des Etudes Démographiques (2004) Taux de mortalité par sexe et âge en 2004. http://www.ined.fr. Accessed March 2008

Institute of Medicine (2000) Appendix 11: human papillomavirus. In: Stratton KR, Durch JS, Lawrence S (eds) Vaccines for the 21st century: a tool for decisionmaking. National Academy Press, Washington, p 213

ISPOR (2010) Pharmacoeconomic guidelines around the world. http://www.ispor.org/PEguidelines/index.asp. Accessed September 2010

Kim JJ, Brisson M, Edmunds WJ, Goldie SJ (2008) Modeling cervical cancer prevention in developed countries. Vaccine 26(Suppl 10):K76–K86PubMedCrossRef

Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M (2007) Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96(1):143–150PubMedCrossRef

Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6):781–789PubMedCrossRef

Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G (2009) Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 27(2):127–147PubMedCrossRef

Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727–735PubMedCrossRef

Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285(23):2995–3002PubMedCrossRef

Munoz N, Castellsague X, Gonzalez ABd, Gissmann L (2006) Chapter 1. Human papillomavirus in the etiology of human cancer. Vaccine 24(Suppl 3):S1–S10CrossRef

Myers ER, GreenS, Lipkus I (2004) Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. (Abstract n° 542 presented at the Twenty-first International Papillomavirus Conference, Mexico City, Mexico. February 20–27)

Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358(9295):1782–1783PubMedCrossRef

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314PubMedCrossRef

Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Arveux P, Seilles E, Mougin C (1999) Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 8(3):157–164PubMedCrossRef

Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL (2008) Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine 26(Suppl 5):F46–F58PubMedCrossRef

Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A (2009) Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374(9706):1975–1985PubMedCrossRef

Sanders GD, Taira AV (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9(1):37–48PubMed

Schaffer P, Sancho-Garnier H, Fender M, Dellenbach P, Carbillet JP, Monnet E, Gauthier GP, Garnier A (2000) Cervical cancer screening in France. Eur J Cancer 36(17):2215–2220PubMedCrossRef

Skinner R, Apter D, Chow SN, Wheeler C, Dubin G (2009) Cross-protection efficacy of Cervarix(tm) against oncogenic HPV types beyond HPV-16/18. (Abstract n° O-29.01 presented at the 25th International Papillomavirus Conference, Malmö, Sweden, May 8–14)

Stanley M, Lowy DR, Frazer I (2006) Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24(Suppl 3):S106–S113CrossRef

Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B (2008) Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26(Suppl 5):F29–F45PubMedCrossRef

Szarewski A (2010) HPV vaccine: Cervarix. Expert Opin Biol Ther 10(3):477–487PubMedCrossRef

Tjalma W, Paavonen J, Naud P, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Garland S, Szarewski A, Romanowski B, Aoki D, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population. (Abstract n° A-171-0004-01446 presented at the 16th International Meeting of the European Society for Gynaecological Oncology (ESGO), Belgrade, Serbia, October 11–14 )

Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1):S1–S15PubMed

Van De Velde N, Brisson M, Boily MC (2007) Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 165(7):762–775PubMedCrossRef

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19PubMedCrossRef

Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices–modeling studies. Value Health 6(1):9–17PubMedCrossRef

Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, Bajos N (2006) Sexual behaviour in context: a global perspective. Lancet 368(9548):1706–1728PubMedCrossRef

Wheeler C, HPV Patricia Study Group (2010) Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in reducing abnormal cytology and against lesions associated with vaccine and non-vaccine oncogenic types: an analysis of women negative for specific HPV types at baseline. (Abstract presented at THE European Research Organisation on Genital Infection and Neoplasia (EUROGIN), Monte Carlo, Monaco, February 17–20)

WHO/ICO (2010) Information centre on HPV and cervical cancer. http://www.who.int/hpvcentre/statistics/dynamic/ico/DataQuerySelect.cfm. Accessed February 2010

zur Hausen H (1996) Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 122(1):3–13PubMedCrossRef

Title: A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer
Authors: Nadia Demarteau
Bruno Detournay
Bertrand Tehard
Abdelkader El Hasnaoui
Baudouin Standaert
Publication date: 01-04-2011
Publisher: SP Birkhäuser Verlag Basel
Published in: International Journal of Public Health / Issue 2/2011
Print ISSN: 1661-8556
Electronic ISSN: 1661-8564
DOI: https://doi.org/10.1007/s00038-010-0216-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

Abstract

Objective

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

Perceived barriers to the development of modern public health in Bulgaria: a qualitative study

Predictors of family communication of one’s organ donation intention in Switzerland

Interviewer gender and self-reported sexual behavior and mental health among male military personnel

Health literacy in a population of primary health-care patients in Belgrade, Serbia

What have we learned? A review of the literature on children’s health and the environment in the Aral Sea area

Decomposing income-related inequality in cervical screening in 67 countries